Genomed S.A.
Genomed S.A. operates in various business sectors.
Genomed S.A. (GEN) - Net Assets
Latest net assets as of : zł- PLN
Based on the latest financial reports, Genomed S.A. (GEN) has net assets worth zł- PLN as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł-) and total liabilities (zł-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Genomed S.A. - Net Assets Trend (None–None)
This chart illustrates how Genomed S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genomed S.A. (None–None)
The table below shows the annual net assets of Genomed S.A. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Genomed S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Genomed S.A. Competitors by Market Cap
The table below lists competitors of Genomed S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MARUHA NICHIRO
BE:6MN
|
$69.81K |
|
TEEKAY
MU:TCD
|
$69.82K |
|
RICOH (RIC1.SG)
STU:RIC1
|
$69.94K |
|
Psyence Group Inc
PINK:PSYGF
|
$70.01K |
|
VTECH HLDGS
MU:VTCB
|
$69.68K |
|
Jack Nathan Medical Corp
OTCQB:JNHMF
|
$69.68K |
|
Shinhan Inverse Corn Futures ETN(H)
KO:500014
|
$69.65K |
|
Ao World
LSE:AO
|
$69.63K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomed S.A.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Genomed S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomed S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Genomed S.A.'s net assets metrics with peer companies in the same industry.
No peer company data available for comparison.